Judy Y Ou1, Rochelle R Smits-Seemann2, Sapna Kaul3, Mark N Fluchel4, Carol Sweeney5, Anne C Kirchhoff6. 1. Cancer Control and Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, United States; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Utah School of Medicine, Salt Lake City, UT 84113, United States. Electronic address: Judy.ou@hci.utah.edu. 2. Department of Institutional Research and Reporting, Salt Lake Community College, Salt Lake City, UT 84123, United States. 3. Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX 77555, United States. 4. Cancer Control and Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, United States; Department of Pediatric Hematology/Oncology, Salt Lake City Primary Children's Hospital, UT 84132, United States. 5. Cancer Control and Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, United States; Division of Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, United States. 6. Cancer Control and Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, United States; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Utah School of Medicine, Salt Lake City, UT 84113, United States.
Abstract
BACKGROUND: Acute Lymphoblastic Leukemia (ALL) has a high survival rate, but cancer-related late effects in the early post-treatment years need documentation. Hospitalizations are an indicator of the burden of late effects. We identify rates and risk factors for hospitalization from five to ten years after diagnosis for childhood and adolescent ALL survivors compared to siblings and a matched population sample. METHODS: 176 ALL survivors were diagnosed at ≤22 years between 1998 and 2008 and treated at an Intermountain Healthcare facility. The Utah Population Database identified siblings, an age- and sex-matched sample of the Utah population, and statewide inpatient hospital discharges. Sex- and birth year-adjusted Poisson models with Generalized Estimating Equations and robust standard errors calculated rates and rate ratios. Cox proportional hazards models identified demographic and clinical risk factors for hospitalizations among survivors. RESULTS: Hospitalization rates for survivors (Rate:3.76, 95% CI=2.22-6.36) were higher than siblings (Rate:2.69, 95% CI=1.01-7.18) and the population sample (Rate:1.87, 95% CI=1.13-3.09). Compared to siblings and population comparisons, rate ratios (RR) were significantly higher for survivors diagnosed between age 6 and 22 years (RR:2.87, 95% CI=1.03-7.97 vs siblings; RR:2.66, 95% CI=1.17-6.04 vs population comparisons). Rate ratios for diagnosis between 2004 and 2008 were significantly higher compared to the population sample (RR:4.29, 95% CI=1.49, 12.32), but not siblings (RR:2.73, 95% CI=0.54, 13.68). Survivors originally diagnosed with high-risk ALL did not have a significantly higher risk than siblings or population comparators. However, high-risk ALL survivors (Hazard ratio [HR]:3.36, 95% CI=1.33-8.45) and survivors diagnosed from 2004 to 2008 (HR:9.48, 95% CI=1.93-46.59) had the highest risk compared to their survivor counterparts. CONCLUSIONS: Five to ten years after diagnosis is a sensitive time period for hospitalizations in the ALL population. Survivors of childhood ALL require better long-term surveillance.
BACKGROUND:Acute Lymphoblastic Leukemia (ALL) has a high survival rate, but cancer-related late effects in the early post-treatment years need documentation. Hospitalizations are an indicator of the burden of late effects. We identify rates and risk factors for hospitalization from five to ten years after diagnosis for childhood and adolescent ALL survivors compared to siblings and a matched population sample. METHODS: 176 ALL survivors were diagnosed at ≤22 years between 1998 and 2008 and treated at an Intermountain Healthcare facility. The Utah Population Database identified siblings, an age- and sex-matched sample of the Utah population, and statewide inpatient hospital discharges. Sex- and birth year-adjusted Poisson models with Generalized Estimating Equations and robust standard errors calculated rates and rate ratios. Cox proportional hazards models identified demographic and clinical risk factors for hospitalizations among survivors. RESULTS: Hospitalization rates for survivors (Rate:3.76, 95% CI=2.22-6.36) were higher than siblings (Rate:2.69, 95% CI=1.01-7.18) and the population sample (Rate:1.87, 95% CI=1.13-3.09). Compared to siblings and population comparisons, rate ratios (RR) were significantly higher for survivors diagnosed between age 6 and 22 years (RR:2.87, 95% CI=1.03-7.97 vs siblings; RR:2.66, 95% CI=1.17-6.04 vs population comparisons). Rate ratios for diagnosis between 2004 and 2008 were significantly higher compared to the population sample (RR:4.29, 95% CI=1.49, 12.32), but not siblings (RR:2.73, 95% CI=0.54, 13.68). Survivors originally diagnosed with high-risk ALL did not have a significantly higher risk than siblings or population comparators. However, high-risk ALL survivors (Hazard ratio [HR]:3.36, 95% CI=1.33-8.45) and survivors diagnosed from 2004 to 2008 (HR:9.48, 95% CI=1.93-46.59) had the highest risk compared to their survivor counterparts. CONCLUSIONS: Five to ten years after diagnosis is a sensitive time period for hospitalizations in the ALL population. Survivors of childhood ALL require better long-term surveillance.
Authors: Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Daniel M Green; Cheryl L Cox; Liang Zhu; Kevin R Krull; Deo Kumar Srivastava; Marilyn Stovall; Vikki G Nolan; Kirsten K Ness; Sarah S Donaldson; Kevin C Oeffinger; Lillian R Meacham; Charles A Sklar; Gregory T Armstrong; Leslie L Robison Journal: J Clin Oncol Date: 2011-12-19 Impact factor: 44.544
Authors: Anne C Kirchhoff; Mark N Fluchel; Jennifer Wright; Jian Ying; Carol Sweeney; Julia Bodson; Antoinette M Stroup; Ken R Smith; Alison Fraser; Anita Y Kinney Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-12 Impact factor: 4.254
Authors: Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe Journal: Blood Date: 2008-02-19 Impact factor: 22.113
Authors: M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider Journal: J Clin Oncol Date: 1996-01 Impact factor: 44.544
Authors: Stefan Essig; Qiaozhi Li; Yan Chen; Johann Hitzler; Wendy Leisenring; Mark Greenberg; Charles Sklar; Melissa M Hudson; Gregory T Armstrong; Kevin R Krull; Joseph P Neglia; Kevin C Oeffinger; Leslie L Robison; Claudia E Kuehni; Yutaka Yasui; Paul C Nathan Journal: Lancet Oncol Date: 2014-06-19 Impact factor: 41.316
Authors: Glenn Flores; Hua Lin; Candy Walker; Michael Lee; Alberto Portillo; Monica Henry; Marco Fierro; Kenneth Massey Journal: Int J Equity Health Date: 2016-03-22
Authors: Lang Li; Tammy Sajdyk; Ellen M L Smith; Chien Wei Chang; Claire Li; Richard H Ho; Raymond Hutchinson; Elizabeth Wells; Jodi L Skiles; Naomi Winick; Paul L Martin; Jamie L Renbarger Journal: Clin Pharmacol Ther Date: 2019-01-21 Impact factor: 6.875
Authors: Gitte Vrelits Sørensen; Jeanette Falck Winther; Sofie de Fine Licht; Klaus Kaa Andersen; Anna Sällfors Holmqvist; Laura Madanat-Harjuoja; Laufey Tryggvadottir; Andrea Bautz; Timothy L Lash; Henrik Hasle Journal: J Natl Cancer Inst Date: 2019-09-01 Impact factor: 13.506
Authors: Judy Y Ou; Heidi A Hanson; Joemy M Ramsay; Claire L Leiser; Yue Zhang; James A VanDerslice; C Arden Pope; Anne C Kirchhoff Journal: Int J Environ Res Public Health Date: 2019-03-26 Impact factor: 3.390
Authors: Eleanor Kane; Sally Kinsey; Audrey Bonaventure; Tom Johnston; Jill Simpson; Debra Howell; Alexandra Smith; Eve Roman Journal: BMJ Open Date: 2022-03-07 Impact factor: 2.692